Navigation Links
Propofol poses low risk in pediatric imaging studies, but risk increases with anesthesia duration
Date:6/9/2010

Washington, DCA new study finds that propofol, a well-known anesthesia medication, has a low occurrence of adverse events for children undergoing research-driven imaging studies. The study, led by a pediatric anesthesiologist now at Children's National Medical Center, showed a low incidence of adverse events and no long term complications when propofol was used to sedate children for imaging studies that require them to be still for long periods of time.

Lead author Zena Quezado, MD, director of the Pain Neurobiology Laboratory at the Sheikh Zayed Institute for Pediatric Surgical Innovation, also found, however, that propofol, a commonly used anesthetic, does show an increased risk for respiratory, cardiovascular, and other side effects if anesthesia is administered over a long period of time or if the child has other complicating factors, including some systemic disease or an airway abnormality. It is also the first imaging study to show an increase in risk to the child with each 30 minute increment a child was under anesthesia.

The findings will help Institutional Review Boards and parents, who are dealing with the ethics debate around research involving children, evaluate the risk-benefit ratio of proposed studies, particularly those involving prolonged imaging studies.

"Getting a child to remain still in an uncomfortable environment during a medical imaging procedure, such an MRI or CT scan, where bodily movement undermines the procedure's quality, is a near impossible task, which is why anesthesia is commonly used," Dr. Quezado said. "We know that propofol can be safely administered in pediatric research studies by well-trained anesthesiologists who are prepared to anticipate and respond to all events, which minimizes the risk of adverse issues. We are applying the findings of this research immediately in our own work, and will help others ensure that every study involving children is safe, ethical and effective."

The study reviews 1,480 propofol anesthetics in 607 children over an eight year period at the NIH's Clinical Research Center and appears in the June 7 issue of Archives of Pediatric and Adolescent Medicine. A total of 98 notable events were observed in 63 patients. Only one event led to an escalation of planned therapy. No events led to prolonged hospitalization.

The increased risk related to severity of systemic disease is in concert with clinical studies that show increasingly severe systemic disease is associated with an increased risk for anesthesia related complications, while patients with airway abnormalities are predisposed to airway obstruction.

Dr. Quezado recently joined Children's National Medical Center from NIH. She plays a leading role in the Sheikh Zayed Institute's Pain Medicine Initiative, which aims to improve surgical outcomes through the reduction and elimination of pain. The Institute creates unprecedented opportunities for cross-disciplinary collaborations among leaders from a broad spectrum of sciences, united under one roof to expedite the research into development of more effective treatments.

Team science is often talked about but rarely achieved," Quezado said. "The Institute's balance between clinical and research work and its robust support of truly collaborative partnerships among doctors and scientists, provides tremendous translational research opportunities. That allows us to advance research more quickly and build upon studies like this one, in our ultimate quest to eliminate pain and improve outcomes for children."


'/>"/>

Contact: Emily Dammeyer
edammeye@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related biology news :

1. DNA barcoding exposes fake ferns in international plant trade
2. Linheng Li proposes novel theory for mammalian stem cell regulation
3. New, virulent strain of MRSA poses renewed antibiotic resistance concerns
4. Type 2 diabetes gene predisposes children to obesity
5. Treatment not testicular cancer poses greatest risk to survivors long-term health
6. Daily consumption of cannabis predisposes to the appearance of psychosis and schizophrenia
7. New asthma research opposes current drug treatment, says UH prof
8. Research exposes the risk to infants from the chemicals used in liquid medicines
9. Research exposes new target for malaria drugs
10. Baker Institute report proposes strategies to ensure global energy security
11. Use of nanomaterials in food packaging poses regulatory challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):
(Date:6/16/2017)... ... June 16, 2017 , ... Cognition Corporation , ... two more sessions of its “From the Helm” Webinar Series. , The ... online templates for design control exercises. Led by David Cronin, Cognition’s CEO, the ...
(Date:6/15/2017)... ... 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer therapeutics ... in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, ... The Series B funding will enable Cybrexa to complete the build-out of its ...
(Date:6/15/2017)... ... 15, 2017 , ... Adam Equipment, a leading provider of ... lab workstation. The guide outlines the procedure in four simple steps, using comprehensive ... anti-vibration table, OIML/ASTM certified weights, and Adam DU specialized software. , A lab ...
(Date:6/14/2017)... USA – , ... ... June 14, 2017 -- Diagenode, a leading global provider ... has licensed a new technology specific for ChIP-sequencing from ... immunoprecipitation followed by sequencing (ChIP-seq) allows the study of ...
Breaking Biology Technology: